Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

Chimeric Antigen Receptor-T Cell Therapy for Solid Tumors Require New Clinical Regimens

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

A long way to the battlefront: CAR T cell therapy against solid cancers.

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

Chimeric antigen receptor-natural killer cells: Novel insight into immunotherapy for solid tumors (Review)

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies

Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments

Current Progress in CAR-T Cell Therapy for Solid Tumors

Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy

The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors

CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances

CAR-T in solid tumors: Blazing a new trail through the brambles

New Chimeric Antigen Receptor Design for Solid Tumors

Bright future or blind alley? CAR-T cell therapy for solid tumors